Literature DB >> 23667211

Double-crossed: why crossover in clinical trials may be distorting medical science.

Vinay Prasad1.   

Abstract

Mesh：

Year:  2013        PMID： 23667211     DOI： 10.6004/jnccn.2013.0077

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN： 1540-1405            Impact factor:   11.908


× No keyword cloud information.
  5 in total

1.  Hard-Wired Bias: How Even Double-Blind, Randomized Controlled Trials Can Be Skewed From the Start.

Authors:  Vinay Prasad; Vance W Berger
Journal:  Mayo Clin Proc       Date:  2015-08-12       Impact factor: 7.616

2.  Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs.

Authors:  Chul Kim; Vinay Prasad
Journal:  Mayo Clin Proc       Date:  2016-05-10       Impact factor: 7.616

3.  Limitations in Clinical Trials Leading to Anticancer Drug Approvals by the US Food and Drug Administration.

Authors:  Talal Hilal; Miguel Gonzalez-Velez; Vinay Prasad
Journal:  JAMA Intern Med       Date:  2020-08-01       Impact factor: 21.873

4.  Trends in the crossover of patients in phase III oncology clinical trials in the USA.

Authors:  Justin Yeh; Shruti Gupta; Sunny J Patel; Vamsi Kota; Achuta K Guddati
Journal:  Ecancermedicalscience       Date:  2020-11-13

5.  When is crossover desirable in cancer drug trials and when is it problematic?

Authors:  A Haslam; V Prasad
Journal:  Ann Oncol       Date:  2018-05-01       Impact factor: 51.769
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.